Regeneron Pharmaceuticals REGN Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's operating income?
- Regeneron Pharmaceuticals (REGN) reported operating income of $642.9M in Q1 2026.
- How has Regeneron Pharmaceuticals's operating income changed year-over-year?
- Regeneron Pharmaceuticals's operating income increased by 8.7% year-over-year, from $591.7M to $642.9M.
- What is the long-term trend for Regeneron Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's operating income has grown at a -20.5% compound annual growth rate (CAGR), from $8.95B to $3.58B.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.